Gordian Surgical Secures $3 Million Funding to Advance Commercialization of TroClose 1200 Laparoscopic Closure System

On October 31, 2019, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that medical device company Gordian Surgical announced the completion of a $3 million financing round. The round was led by Trendlines Group and the Israel Innovation Authority, with the specific series not disclosed.

It is reported that Gordian Surgical will use the funds from this round of financing to accelerate the commercialization of its laparoscopic closure system, TroClose 1200.

Gordian Surgical, established in 2012 and headquartered in the Northern District of Israel, is a medical device company. The company is dedicated to developing novel laparoscopic closure systems, providing advanced medical equipment for laparoscopic surgery. Gordian Surgical holds patents for three products, including laparoscopic trocars, fascial closure systems, and suture anchor deployment systems.

Gordian Surgical’s lead candidate product is the TroClose 1200 Laparoscopic System, an integrated port-closure system that replaces manual suturing and provides surgeons with a simple, reliable, and safe surgical solution. The system enables opening and closure of the abdominal wall during laparoscopic procedures and has received U.S. FDA clearance and EU CE marking.

TroClose 1200 is equipped with a unique “two-in-one” suture device, trocar, and two absorbable anchors, which effectively introduce absorbable sutures into the peritoneal tissue and secure the trocar during surgery. After trocar removal, surgeons can directly close the fascia using the TroClose 1200 system, significantly reducing the risk of hernia due to inadequate closure of laparoscopic ports.

Zvi Pe'er, CEO of Gordian Surgical, stated, “This financing will scale up the commercialization efforts of Gordian Surgical. We will continue to expand our presence in the U.S. market and export our products to countries in Europe and Latin America. The TroClose 1200 laparoscopic system from Gordian Surgical has obtained FDA clearance in the United States and CE marking in the European Union, backed by clinical data from more than 2,000 procedures. We are committed to developing innovative products to enhance the safety of knee surgeries and meet patients’ clinical needs.”

“TroClose 1200 has been used in over 3,000 surgical cases to date. We aim to expand its availability to other international markets, providing innovative laparoscopic solutions for healthcare professionals and patients,” said Todd Dollinger, Chairman and CEO of Trendlines Group.

Trendlines Group, established in 1993 and headquartered in Northern Israel, is a publicly traded venture capital firm. The company focuses on investing in life sciences, clean technology, IT, and other markets, while helping enterprises pioneer innovative business ventures. Since its inception, Trendlines Group has completed 21 investments.

Israel Innovation Authority, established in 1965 and headquartered in Jerusalem, Israel, is an investment office. The agency primarily provides support to local research institutes and life sciences enterprises, promoting the export trade of high-tech products.

(Compiled by Xu Xiaoxue)